Results 141 to 150 of about 63,889 (276)

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Isha J. Patel, Cynthia Levy, Craig Lammert, Raghav Bordia, Duru Cosar, Katherine Specht, Daniel Pratt, Stuart C. Gordon, Lisa Forman, Fawzy Barry, Michael Li, Usha Gungabissoon, Megan M. McLaughlin, Christopher L. Bowlus   +16 more
wiley   +1 more source

Pathogen‐Specific Bloodstream Infections Associated With Tumour Necrosis Factor‐α Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case‐Control Study 2010–2024

Alimentary Pharmacology &Therapeutics, EarlyView.
In this nationwide study of patients with inflammatory bowel disease, TNF inhibitor use was associated with higher bloodstream infection rates, whereas vedolizumab and ustekinumab was not. Associations differed by pathogen species, and concomitant glucocorticoid use was associated with higher infection rates.
Cæcilie Leding, Alessandra Meddis, Jon Gitz Holler, Johan Burisch, Thomas Benfield   +4 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Early infliximab levels and clearance predict outcomes in acute severe ulcerative colitis. [PDF]

Transl Gastroenterol Hepatol
Al Hayek M, Elhadi M.
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

The TITAN Study: Topical Infliximab for the Treatment of Advanced Corneal Melt and Ocular Surface Inflammation. [PDF]

Ophthalmol Sci
Bouhout S, Geoffrion D, Bostan C, Jabbour S, Robert MC.   +4 more
europepmc   +1 more source

Are Ocular Markers of Sun Exposure Associated With Skin Cancer? A Cross‐Sectional Analysis of the Busselton Healthy Ageing Study

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Higher past sun or ultraviolet radiation exposure increases the risk of skin cancer and three common ocular findings: pterygium, conjunctival ultraviolet autofluorescence (CUVAF) and myopia. We investigated whether ocular markers of past sun exposure are associated with a history of skin cancer.
Gareth Lingham, Vinay Kumar Nilagiri, Holly Brown, Chrianna Bharat, Samantha S. Y. Lee, Maria Franchina, Michael Hunter, Kevin Murray, David Alonso‐Caneiro, Catherine M. Olsen, David C. Whiteman, David A. Mackey   +11 more
wiley   +1 more source

Infliximab-induced Remission of Postoperative Pyoderma Gangrenosum: A Case Report and Literature Review. [PDF]

Plast Reconstr Surg Glob Open
Pratanrit P, Pratumchart N, Chanprapaph K, Jirasiritham S, Rattanakaemakorn P.   +4 more
europepmc   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara, Tanja Tran, Sandeep Kiri, Romy Bley, Kathrin Schlüter, Claudia Grellmann, Sima Melnik, Sylke Schneider‐Burrus   +7 more
wiley   +1 more source

Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn's Disease. [PDF]

Clin Pharmacokinet
Nasr A, Mizuno T, Irie K, Dillman JR, Jackson K, Lynch K, Horrell A, Aviles T, Chun K, Yang J, Boyle B, Hyams JS, Noe J, Denson LA, Minar P.   +14 more
europepmc   +1 more source